ANVS

In a report released yesterday, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Annovis Bio (ANVS - Research Report), with a price target of $40.00. The company's shares closed yesterday at $12.55.Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Genmab, and Aquestive Therapeutics. According to TipRanks, Selvaraju has an average return of -33.6% and a 16.92% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Annovis Bio with a $33.00 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-annovis-bio-anvs?utm_source=advfn.com&utm_medium=referral